705064_r-biopharmnews_2_07_gb.indd

Lupins and lupin products
Lupin fl our is often used in meat produc- Directive 2003/89/EC), taking effect from also declare ingredients such as lupins and lupin products in the ingredients list.
In order to comply with these new legislative of analysis available to our customers, R-Biopharm decided to incorporate the new real-time PCR Test, SureFood®Allergen
Lupin from our partner Congen, Berlin,
into its product portfolio. The test has been use of lupin proteins is causing a rise in available since the end of April under article allergic reactions against lupin for many consumers. Lupin fl our presents a hazard for peanut allergy suffers, in particular, as a In addition, we are currently working on the development of an ELISA test system for lupin determination. We plan to launch this new product on the market at the end of the year.
About our products
RIDASCREEN® Gliadin competitive (R7011)
Celiac disease is permanent gluten intole- Gliadin competitive ELISA (R7011) so as to keep abreast of this development and to be in a position to offer our customers the are reversible with a gluten-free diet.
best and most reliable method of analysis for detecting gliadin in a variety of different foods, with chemical or enzymatic pro-cesses, the gluten molecule is denatured RIDASCREEN® Gliadin competitive is a com- into small fragments (peptides) of different petitive enzyme immunoassay for quantita- sizes. These peptides in turn may also be of prolamins from wheat (gliadine), rye (secalin) and barley (hordein) in foodstuffs and can be used to investigate starch, syrup our RIDASCREEN® Gliadin test (R7001) in and beer. The specifi city of the monoclonal sandwich-ELISA format various scientifi c R5 antibody is so high that it is capable groups, in particularly Prof. Mendez’ group in Spain, have continued research into the with a sequence of 5 – 10 amino acids. detection of gliadin in food samples. They fi rst test on the market to detect gluten has only a limited suitability for detecting The RIDASCREEN® Gliadin test requires at the test has been offi cially available since least two epitopes (antibody binding sites) to form a sandwich complex. Small peptide fragments can be produced with hydrolysis, which, due to their size, only have one epitope and it is therefore impossible for a sandwich complex to form. This means that these small fragments produced by hydro-lysis are not measured. RIDA®QUICK Afl atoxin (R5204)
• grains (maize, wheat, barley, rye, oats, • nuts (peanut, hazelnut, almond, Brazil Two further application notes are available on request for ginger and nutmeg, as well as for paprika, chilli and pepper.
RIDA®QUICK DON (R5904)
appears for positive samples, which is not available since April 2007. Just as it was the case for RIDA®QUICK Afl atoxin (R5204), the test was developed by R-Biopharm and previous test, which are listed in the follow- Interpretation of results is made consider-ably easier, whereby a visible test band RIDA®QUICK DON
according to the extraction procedure approx. 1.25 mg/kg (ppm) orapprox. 0.5 mg/kg (ppm) DON content ͧ 1.25 mg/kg (ppm)(1 g sample + 40 ml extraction buffer) DON content ͧ 0.5 mg/kg (ppm) (1 g sample + 15 ml extraction buffer) DON content < 1.25 mg/kg (ppm)(1 g sample + 40 ml extraction buffer) DON content < 0.5 mg/kg (ppm) (1 g sample + 15 ml extraction buffer) test band appears with positive
test band does not appear with
negative samples
EU-wide maximum myotoxin levels
No. 1881/2006 of 19 December 2006 sett-
mycotoxin levels as defi ned in the respec- ing maximum levels for certain contami-
tive EU regulations included in the last issue nants in foodstuffs as a pdf fi le in German
(R-Biopharm News I/07) was unfortunately and English on request from R-Biopharm.
not completely up to date, we apologise for This regulation replaces the preceding ones You have the opportunity of obtaining the current COMMISSION REGULATION (EC)
New application notes
There are several new application notes for RIDASCREEN® Chloramphenicol (R1505) and for RIDASCREEN® Enro/Cipro (R3111) available on request: • Chloramphenicol in serum / plasma
• Chloramphenicol in mixed feed
• Enrofl oxacin and ciprofl oxacin in honey
in combination with RIDA®C18 column (R2002)
If you are interested in our products,
please contact your local distributor.
Product Recalls from food producers –
information from R-Biopharm Rhône, Scotland
Since the beginning of March, there have However, it doesn’t just seem to be compa- been at least 7 product recalls from food nies’ getting into trouble for missing out producers undertaken in the UK. This is due to the failure of companies to include the product, a major retailer has recently been presence of allergens on product labels. The fi ned for claiming an ingredient was present when in fact no detectable levels could be milk, nuts, soya and gluten with their pre- consumers who are either allergic or intole- orange juice where in fact 2 students per- rant. Although the companies involved are forming a school project found evidence to doing their best to ensure that all of the the contrary This lead to the fi rm being affected products are removed the shelves, charged with misleading advertising over a these recalls are still an all too common occurrence particularly since the regulations were introduced back in Nov 2005.
Update on applying EU Feed and Food Controls –
information from R-Biopharm Rhône, Scotland
carried out using internationally recognised published an update on the progress on the protocols or where performance criteria for analytical methods have been established. tion 882/2004 on offi cial controls in the UK. requirements for competent authorities, or have been involved in many trials over the enforcement authorities that are responsible years, earning them the reputation as the for checking that businesses comply with feed and food legislation. The regulations state that food and feed should be safe with There has not been an update since January of this year and this latest update provides duction and marketing of the feed. A parti- information on on-going work at EU level to cular area of interest within the regulation is the characterisation of methods of analysis controls for ’high-risk’ feed and food pro- which states that methods be characterised by criteria such as reproducibility, limits of detection and recoveries amongst others. The precision values referred to should be obtained either through collaborative trials Fairs and conferences
”Vitamins in foodstuffs and food supplements“ conference 13 June 2007 in Darmstadt
The International Association for Cereal Science and Technology (ICC) in cooperation with R-Biopharm AG is organizing a Vitamin Conference in Darmstadt on Wednesday, 13 June 2007. Besides the legislative framework conditions and the nutrition physiological status quo, the focus will also be on new, improved analytical methods. The conference is aimed towards those responsible for quality assurance and the heads of laboratory in industry and in private and offi cial laboratories. Should you have any questions, please contact Stella Lindeke, E-mail: [email protected] or Tel. +49 (0) 61 51-81 02-636. International Association for Cereal Science and Technology (ICC)
Conference and Workshop in Glasgow, Scotland
03.09. – 05.09.2007
Representatives: R-Biopharm Rhône, Glasgow
Preannouncement:
“Food allergens” workshop in Austria
November 2007Two-day workshop consisting of a theoretical and a practical sessionVenue: ViennaJoint event: ICC (International Association for Cereal Science and Technology), AGES (Austrian Agency for Health and Food Safety), Ofi (Austrian Research Institute for Chemistry and Technology) and R-Biopharm AG For further information on the workshops, please contact:Christine M. Gutschelhofer, Tel: +43 (0) 664 135 21 22, E-mail: [email protected] or Skype: c.gutschelhofer The next R-Biopharmnews will be published during the 3rd quarter 2007
R-Biopharmnews is edited by
R-Biopharm AG
Landwehrstrasse 54, 64293 Darmstadt
Germany
Phone: +49 61 51 - 81 02-0
Fax:

Source: http://csoda-alga.shp.hu/hpc/userfiles/r-biopharm/ii_07_engl.pdf